Kronos Bio, Inc. (KRON)

Kronos Bio Statistics

Total Valuation

Kronos Bio has a market cap or net worth of $45.12 million. The enterprise value is -$30.52 million.

Market Cap	45.12M
Enterprise Value	-30.52M

Important Dates

The next estimated earnings date is Tuesday, May 20, 2025, after market close.

Earnings Date	May 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Kronos Bio has 60.97 million shares outstanding. The number of shares has increased by 4.03% in one year.

Current Share Class	60.97M
Shares Outstanding	60.97M
Shares Change (YoY)	+4.03%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	27.83%
Owned by Institutions (%)	32.06%
Float	43.81M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.86
Forward PS	n/a
PB Ratio	0.57
P/TBV Ratio	0.57
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 12.93, with a Debt / Equity ratio of 0.30.

Current Ratio	12.93
Quick Ratio	12.66
Debt / Equity	0.30
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -59.49% and return on invested capital (ROIC) is -23.57%.

Return on Equity (ROE)	-59.49%
Return on Assets (ROA)	-21.73%
Return on Invested Capital (ROIC)	-23.57%
Return on Capital Employed (ROCE)	-50.47%
Revenue Per Employee	$919,200
Profits Per Employee	-$6.45M
Employee Count	10
Asset Turnover	0.06
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -27.44% in the last 52 weeks. The beta is 1.76, so Kronos Bio's price volatility has been higher than the market average.

Beta (5Y)	1.76
52-Week Price Change	-27.44%
50-Day Moving Average	0.85
200-Day Moving Average	0.95
Relative Strength Index (RSI)	39.50
Average Volume (20 Days)	924,242

Short Selling Information

The latest short interest is 671,404, so 1.10% of the outstanding shares have been sold short.

Short Interest	671,404
Short Previous Month	669,437
Short % of Shares Out	1.10%
Short % of Float	1.53%
Short Ratio (days to cover)	6.47

Income Statement

In the last 12 months, Kronos Bio had revenue of $9.19 million and -$64.49 million in losses. Loss per share was -$1.07.

Revenue	9.19M
Gross Profit	9.19M
Operating Income	-50.60M
Pretax Income	-102.85M
Net Income	-64.49M
EBITDA	-49.14M
EBIT	-50.60M
Loss Per Share	-$1.07

Balance Sheet

The company has $99.73 million in cash and $24.09 million in debt, giving a net cash position of $75.65 million or $1.24 per share.

Cash & Cash Equivalents	99.73M
Total Debt	24.09M
Net Cash	75.65M
Net Cash Per Share	$1.24
Equity (Book Value)	79.81M
Book Value Per Share	1.31
Working Capital	93.99M

Cash Flow

In the last 12 months, operating cash flow was -$54.38 million and capital expenditures $3,000, giving a free cash flow of -$65.44 million.

Operating Cash Flow	-54.38M
Capital Expenditures	3,000
Free Cash Flow	-65.44M
FCF Per Share	-$1.07

Margins

Gross Margin	100.00%
Operating Margin	-550.46%
Pretax Margin	-701.53%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kronos Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.03%
Shareholder Yield	-4.03%
Earnings Yield	-142.91%
FCF Yield	-145.02%

Analyst Forecast

The average price target for Kronos Bio is $1.63, which is 120.24% higher than the current price. The consensus rating is "Buy".

Price Target	$1.63
Price Target Difference	120.24%
Analyst Consensus	Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	48.62%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Kronos Bio has an Altman Z-Score of -6.94 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.94
Piotroski F-Score	3